MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2026: Is biotech back? Four drugmakers go public, raising $1 billion total
AgomAb Therapeutics NV(AGMB)
Organization & Developments: AgomAb Therapeutics
Parents
AgomAb Therapeutics NV(AGMB)
Children
2026: AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis (NASDAQ:AGMB) | Seeking Alpha
Regenerative pathway modulators in inflammatory, metabolic and fibrotic diseases.
The pipeline is led by an HGF-mimetic agonistic antibody developed using argenx’s platform.
Using the power of ALK inhibitors—but without the toxicity—to treat a major unmet need in Crohn's disease
Jumps
Finance & Acquisitions: AgomAb Therapeutics
Key People: AgomAb Therapeutics